These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11708189)

  • 21. Nucleoside reverse-transcriptase inhibitor dosing errors in an outpatient HIV clinic in the electronic medical record era.
    Willig JH; Westfall AO; Allison J; Van Wagoner N; Chang PW; Raper J; Saag MS; Mugavero MJ
    Clin Infect Dis; 2007 Sep; 45(5):658-61. PubMed ID: 17683005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Checking up on ddI and tenofovir in people with HIV/AIDS.
    TreatmentUpdate; 2003; 15(3):4-5. PubMed ID: 17216846
    [No Abstract]   [Full Text] [Related]  

  • 23. High rate of virologic failure with once-daily ddI/3TC/TDF.
    IAPAC Mon; 2003 Nov; 9(11):279. PubMed ID: 14989185
    [No Abstract]   [Full Text] [Related]  

  • 24. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial.
    Molina JM; Marcelin AG; Pavie J; Heripret L; De Boever CM; Troccaz M; Leleu G; Calvez V;
    J Infect Dis; 2005 Mar; 191(6):840-7. PubMed ID: 15717257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacological and clinical properties of didanosine (VIDEX), a nucleoside reverse transcriptase inhibitor].
    Okiyama M; Kawashima H; Fukunishi S
    Nihon Yakurigaku Zasshi; 2002 Aug; 120(2):115-22. PubMed ID: 12187624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.
    Sproat M; Pozniak AL; Peeters M; Winters B; Hoetelmans R; Graham NM; Gazzard BG
    Antivir Ther; 2005; 10(2):357-61. PubMed ID: 15865231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine.
    Marcelin AG; Flandre P; Furco A; Wirden M; Molina JM; Calvez V;
    Antivir Ther; 2006; 11(6):693-9. PubMed ID: 17310813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heart attack risk with abacavir and didanosine.
    AIDS Patient Care STDS; 2008 Apr; 22(4):346-7. PubMed ID: 18434947
    [No Abstract]   [Full Text] [Related]  

  • 29. [HIV drug resistance and its genetic basis].
    Tsuchie H; Sakamoto T; Kurimura T
    Nihon Rinsho; 1993 Sep; 51 Suppl():610-4. PubMed ID: 7505854
    [No Abstract]   [Full Text] [Related]  

  • 30. FDA notifications. Large study suggests heart attack risk from use of abacavir or didanosine.
    AIDS Alert; 2008 May; 23(5):58-9. PubMed ID: 18642404
    [No Abstract]   [Full Text] [Related]  

  • 31. [Didanosine].
    Enferm Infecc Microbiol Clin; 1995 Oct; 13(8):487-90. PubMed ID: 8555311
    [No Abstract]   [Full Text] [Related]  

  • 32. Caution issued for HIV combination therapy with Zerit and Videx in pregnant women.
    HIV Clin; 2001; 13(2):6. PubMed ID: 11810823
    [No Abstract]   [Full Text] [Related]  

  • 33. Drugs for HIV infection.
    Medical Letter Inc
    Treat Guidel Med Lett; 2006 Oct; 4(50):67-76. PubMed ID: 16985490
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients.
    Winters MA; Bosch RJ; Albrecht MA; Katzenstein DA;
    J Infect Dis; 2003 Aug; 188(4):537-40. PubMed ID: 12898440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C and didanosine: risk of lactic acidosis.
    Prescrire Int; 2005 Dec; 14(80):222-3. PubMed ID: 16400744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinically relevant genotype interpretation of resistance to didanosine.
    Marcelin AG; Flandre P; Pavie J; Schmidely N; Wirden M; Lada O; Chiche D; Molina JM; Calvez V;
    Antimicrob Agents Chemother; 2005 May; 49(5):1739-44. PubMed ID: 15855490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosine.
    Barreiro P; Soriano V; Valencia E; Díaz B; González-Lahoz J
    AIDS; 2001 Dec; 15(18):2469-70. PubMed ID: 11774839
    [No Abstract]   [Full Text] [Related]  

  • 38. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
    Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
    Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Didanosine once daily: potential for expanded use.
    Pollard RB
    AIDS; 2000 Nov; 14(16):2421-8. PubMed ID: 11101051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.